Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM PHENYLACETATE AND SODIUM BENZOATE vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinic acid synthetase (AS), argininosuccinic acid lyase (AL), or arginase (ARG). Also used for maintenance therapy in chronic management of UCDs.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
The terminal elimination half-life of phenylacetate is approximately 0.5-0.8 hours; however, its active conjugate phenylacetylglutamine has a half-life of about 1.2-1.5 hours. For benzoate, the half-life is approximately 0.5-1 hour. In the context of hyperammonemia treatment, the clinical effect correlates with the rapid formation of conjugates, and the half-life reflects quick clearance. In neonates or patients with renal impairment, half-life may be prolonged.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Sodium phenylacetate is metabolized via conjugation with glutamine to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine to form hippurate. Both metabolites are rapidly excreted by the kidneys.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Sodium phenylacetate and sodium benzoate are primarily excreted renally. Phenylacetate is conjugated with glutamine to form phenylacetylglutamine, which is rapidly eliminated in urine. Benzoate is conjugated with glycine to form hippurate, also renally eliminated. Approximately 80-100% of the administered dose is recovered in urine as conjugates and minor metabolites. Fecal excretion is negligible (<5%).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Phenylacetate and benzoate are highly protein bound, primarily to albumin. Protein binding is approximately 80-90% for phenylacetate and 75-85% for benzoate. Binding may be saturable at high concentrations.
Negligible for electrolytes and dextrose (<5%).
The apparent volume of distribution for both drugs is small, approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. This is consistent with their high protein binding and confinement to the vascular and interstitial spaces.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Oral bioavailability is high, approximately 80-90% for both components, as they are well absorbed. However, for acute hyperammonemia, intravenous administration is preferred to ensure rapid and complete delivery.
Intravenous: 100%.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-50: reduce dose by 50% and monitor ammonia levels.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific adjustment; use with caution in severe hepatic impairment due to potential for increased ammonia.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Same weight-based dosing as adults: 5.5 g/m² IV loading then 5.5 g/m²/24h continuous infusion.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
No specific adjustment; monitor renal function and consider reduced dosing based on creatinine clearance.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
WARNING: Contains sodium (approximately 30.2 mg/m L from sodium phenylacetate and sodium benzoate). Use caution in patients with congestive heart failure, severe renal insufficiency, or conditions with sodium retention. Additionally, neurotoxicity has been associated with phenylacetate accumulation; monitor plasma levels.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Monitor ammonia levels, electrolytes, and neurological status. Risk of hypernatremia due to sodium content. Phenylacetate may cause neurotoxicity (tremors, agitation, coma) at high concentrations. Use with caution in patients with hepatic or renal impairment. Not recommended for patients with known hypersensitivity to phenylacetate or benzoate. Extravasation risk: avoid extravasation; if occurs, treat locally.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Known hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation; pre-existing severe hypernatremia (serum sodium >150 m Eq/L); neonates with hyperbilirubinemia (risk of kernicterus due to benzoate displacing bilirubin from albumin).
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Administer with food or enteral feeding to reduce gastrointestinal irritation. Avoid high-protein meals during treatment as they may increase ammonia production. No specific food-drug interactions; restrict dietary protein as part of urea cycle disorder management (typically 0.5-2 g/kg/day).
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal and visceral malformations) when administered during organogenesis. Human data are insufficient to determine fetal risk. In the first trimester, potential for teratogenicity exists; use only if maternal benefit outweighs risk. Second and third trimester exposure may be associated with neonatal metabolic alkalosis, hypernatremia, and potential for kernicterus due to displacement of bilirubin from albumin. Avoid use during labor and delivery due to risk of neonatal hyperbilirubinemia.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Excretion into human breast milk is unknown. The molecular weight of both sodium phenylacetate and sodium benzoate suggests potential for transfer into breast milk. The Milk-to-Plasma ratio is not established. Because of potential for serious adverse reactions in nursing infants (e.g., metabolic acidosis, neurotoxicity), breastfeeding is not recommended during therapy. Alternative feeding methods should be considered.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Pregnancy-induced hemodilution and increased renal clearance may require dose adjustments to maintain therapeutic ammonia levels. Monitor serum ammonia closely; consider starting at lower doses and titrating based on response. Due to increased plasma volume, distribution volume changes, and enhanced renal excretion, dose adjustments upward may be necessary. However, avoid excessive dosing to prevent maternal metabolic alkalosis or hypernatremia. Individualize therapy based on frequent ammonia monitoring, with consideration of gestational age. Postpartum, dose may need to be reduced as renal function normalizes.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Administer intravenously via central line due to hypertonicity (p H 9-9.5). Monitor serum ammonia, potassium, and bicarbonate closely; hypokalemia and metabolic alkalosis are common. Use with caution in renal impairment (dose adjust for GFR <30 m L/min). Discontinue if hypernatremia or volume overload occurs. Caloric content: 2.5 kcal/m L from phenylacetate and benzoate.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This medication is used to remove excess ammonia from your blood due to a urea cycle disorder.,It is given through a central intravenous line; report any pain, redness, or swelling at the infusion site.,You may experience nausea, vomiting, or headache; notify your healthcare provider if severe.,Regular blood tests are necessary to monitor your ammonia levels and electrolytes.,Avoid taking other medications without consulting your doctor, as they may affect ammonia levels.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM PHENYLACETATE AND SODIUM BENZOATE vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM PHENYLACETATE AND SODIUM BENZOATE is a Ammonia Detoxicant that works by Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM PHENYLACETATE AND SODIUM BENZOATE and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM PHENYLACETATE AND SODIUM BENZOATE is: Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM PHENYLACETATE AND SODIUM BENZOATE and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM PHENYLACETATE AND SODIUM BENZOATE is classified as Category C. FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal an. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.